Treatment of Diabetes in Patients with Heart Failure

Current Cardiology Reports
Christa D BowesJaved Butler

Abstract

This review aims to summarize and discuss heart failure outcomes for current glucose-lowering agents in patients with type 2 diabetes mellitus. Current regulations require cardiovascular outcomes trials for new glucose-lowering therapies to establish that there is no unacceptable increase in cardiovascular risk prior to approval. These cardiovascular outcomes trials include glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors. Overall, 87,162 patients have been studied in 10 published cardiovascular outcomes trials. There was no significant increase in major adverse cardiovascular events including cardiovascular mortality, myocardial infarction, and stroke in any of these trials. Heart failure was a component of the secondary endpoint of all of these trials, but only two of these studies show a significant improvement in rates of hospitalization for heart failure. Expanded regulatory labeling for reduction in cardiovascular mortality (empagliflozin) and reduction in major adverse cardiovascular events (liraglutide) has recently been established. Saxagliptin and to a lesser part alogliptin have been associated with an increased rate of hospitalization for hea...Continue Reading

References

Feb 29, 1996·The New England Journal of Medicine·C J Bailey, R C Turner
Sep 1, 1996·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·F M Ashcroft
Feb 28, 2004·Diabetes Care·Alain G BertoniDavid C Goff
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Sep 13, 2007·JAMA : the Journal of the American Medical Association·A Michael LincoffSteven E Nissen
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Mar 17, 2010·The New England Journal of Medicine·William C CushmanFaramarz Ismail-Beigi
Aug 13, 2010·The Journal of Clinical Endocrinology and Metabolism·Marianne ZellerUNKNOWN French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators
Aug 10, 2011·The American Journal of Cardiology·Michael H Davidson
Jun 13, 2012·The New England Journal of Medicine·Hertzel C GersteinSalim Yusuf
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Jul 25, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·D T EurichF A McAlister
Aug 16, 2015·The Lancet. Diabetes & Endocrinology·Miles FisherJohn J V McMurray
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Jan 29, 2016·European Heart Journal·David FitchettUNKNOWN EMPA-REG OUTCOME® trial investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 25, 2016·Journal of Cardiovascular Medicine·Lorenzo FácilaJulio Núñez
Aug 3, 2016·JAMA : the Journal of the American Medical Association·Kenneth B MarguliesUNKNOWN NHLBI Heart Failure Clinical Research Network
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Apr 21, 2017·Journal of the American Heart Association·Christianne L RoumieMarie R Griffin
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Jan 26, 2018·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Feb 2, 2018·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee
Mar 13, 2018·Circulation·Karin RådholmBruce Neal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Marlys H LeBrasSheri L Koshman
© 2022 Meta ULC. All rights reserved